These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 46704)

  • 1. Uncontrolled diabetes mellitus and hyperglucagonemia associated with an islet cell carcinoma.
    Leichter SB; Pagliara AS; Grieder MH; Pohl S; Rosai J; Kipnis DM
    Am J Med; 1975 Feb; 58(2):285-93. PubMed ID: 46704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A glucagonoma syndrome.
    Mallinson CN; Bloom SR; Warin AP; Salmon PR; Cox B
    Lancet; 1974 Jul; 2(7871):1-5. PubMed ID: 4134714
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of intermittent physiologic hyperglucagonemia on postprandial plasma glucose levels in normal man.
    Mackes K; Rizza R; Gerich J
    Metabolism; 1981 Nov; 30(11):1041-4. PubMed ID: 7026969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin and glucagon in rats with islet cell tumors induced by small doses of streptozotocin.
    Yoshino G; Kazumi T; Morita S; Baba S
    Can J Physiol Pharmacol; 1981 Aug; 59(8):818-23. PubMed ID: 6271376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma.
    Valverde I; Lemon HM; Kessinger A; Unger RH
    J Clin Endocrinol Metab; 1976 May; 42(5):804-8. PubMed ID: 178682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycemia in type I diabetes. Evidence for an effect mediated by beta-adrenoreceptors.
    Bolli G; de Feo P; Compagnucci P; Cartechini MG; Angeletti G; Santeusanio F; Brunetti P
    Diabetes; 1982 Jul; 31(7):641-7. PubMed ID: 6298039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma glucagon in insulinoma.
    Ohneda A; Matsuda K; Horigome K; Ishii S; Yanbe A; Maruhama Y
    Acta Diabetol Lat; 1977; 14(5-6):219-28. PubMed ID: 207064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin and glucagon secretion in diabetic and non-diabetic patients with circulating islet cell antibodies.
    Tiengo A; Del Prete GF; Nosadini R; Betterle C; Garotti C; Bersani G
    Diabetologia; 1977 Sep; 13(5):451-8. PubMed ID: 332569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic studies and glucagon gel filtration pattern before and after surgery in a case of glucagonoma syndrome.
    von Schenck H; Thorell JI; Berg J; Bojs G; Dymling JF; Hallengren B; Ljungberg O; Tibblin S
    Acta Med Scand; 1979; 205(3):155-62. PubMed ID: 218426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.
    Rizza R; Verdonk C; Miles J; Service FJ; Gerich J
    J Clin Invest; 1979 Jun; 63(6):1119-23. PubMed ID: 447838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished insulin and glucagon secretory responses to arginine in nondiabetic subjects with a mutation in the hepatocyte nuclear factor-4alpha/MODY1 gene.
    Herman WH; Fajans SS; Smith MJ; Polonsky KS; Bell GI; Halter JB
    Diabetes; 1997 Nov; 46(11):1749-54. PubMed ID: 9356021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Islet cell adenoma in the newborn: report of two patients.
    Robinson MJ; Clarke AM; Gold H; Connelly JF
    Pediatrics; 1971 Aug; 48(2):232-6. PubMed ID: 4327109
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pancreatic function tests].
    Abe M; Ikeda Y; Yaginuma M; Shimizu N
    Nihon Rinsho; 1969 Feb; 27(2):291-300. PubMed ID: 4306418
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus.
    Popp DA; Shah SD; Cryer PE
    J Clin Invest; 1982 Feb; 69(2):315-26. PubMed ID: 6120181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion.
    Bolli G; de Feo P; Compagnucci P; Cartechini MG; Angeletti G; Santeusanio F; Brunetti P; Gerich JE
    Diabetes; 1983 Feb; 32(2):134-41. PubMed ID: 6337896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glucagonoma syndrome.
    Shupack JL; Berczeller PH; Stevens DM
    J Dermatol Surg Oncol; 1978 Mar; 4(3):242-7. PubMed ID: 204668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of somatostatin and somatostatin analogs in a patient with a glucagonoma.
    Kahn CR; Bhathena SJ; Recant L; Rivier J
    J Clin Endocrinol Metab; 1981 Sep; 53(3):543-9. PubMed ID: 6114963
    [No Abstract]   [Full Text] [Related]  

  • 18. Abnormalities of endogenous glucagon and insulin in unstable diabetes.
    Reynolds C; Molnar GD; Horwitz DL; Rubenstein AH; Taylor WF; Jiang NS
    Diabetes; 1977 Jan; 26(1):36-45. PubMed ID: 830563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic effects of chronic hyperglucagonaemia.
    Nankervis A; Proietto J; Ng KW; Alford FP; Larkins R
    Clin Endocrinol (Oxf); 1981 Oct; 15(4):325-33. PubMed ID: 6274544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory response and immunochemical heterogeneity of glucagon in plasma and tumor extracts of a patient with glucagonoma.
    Torre L; Vazquez JA; Blázquez E
    Horm Res; 1986; 23(3):159-66. PubMed ID: 3005153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.